Table 4. Prognostic factors (univariate and multivariate analysis) for overall survival among aggressively-treated patients with blastic plasmacytoid dendritic cell neoplasms (n = 25).
| Patient features | % of cases | Median (months) | Uni P- value | Multi P- value | Hazard Ratio | 95% CI | |
|---|---|---|---|---|---|---|---|
| Age | ≤ 15 y | 16 | NR | .04 | |||
| > 15 y | 84 | 14 | |||||
| Adenopathies | No | 52 | 22 | .03 | |||
| Yes | 48 | 10 | |||||
| Hepatomegaly | No | 72 | 17 | .03 | |||
| Yes | 28 | 11 | |||||
| Skin involvement | No | 44 | 23 | .04 | |||
| Yes | 56 | 11 | |||||
| Leukopenia (< 4 × 109/l) | No | 74 | 11 | .05 | |||
| Yes | 26 | 23 | |||||
| Elevated LDH (≥ 450U/l) | No | 36 | 23 | .001 | .005 | 6.6 | 1.8 – 24.8 |
| Yes | 64 | 10 | |||||
| Increased β2-M (≥ 3 mg/l) | No | 43 | 42 | .02 | |||
| Yes | 57 | 10 | |||||
| ALL-type treatment | No | 28 | 10 | .03 | |||
| Yes | 72 | NR | |||||
| AHSC transplantation | No | 80 | 11 | .04 | |||
| Yes | 20 | NR | |||||
| Relapse | No | 32 | NR | .02 | |||
| Yes | 68 | 14 |
Uni: univariate analysis, Multi: multivariate analysis, CI: confidence interval, NR: not reached, LDH: lactate dehydrogenase, β2-M: β2-microglobulin, ALL: acute lymphoblastic leukemia, AHSC: allogeneic hematopoietic stem cell.